<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859050</url>
  </required_header>
  <id_info>
    <org_study_id>HS-3131</org_study_id>
    <nct_id>NCT03859050</nct_id>
  </id_info>
  <brief_title>Alveolar Macrophage Programming Following Endotoxin Exposure</brief_title>
  <official_title>Alveolar Macrophage Programming Following Endotoxin Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in
      the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of
      epithelial-capillary integrity and accumulation of edema fluid in the interstitium and
      airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and
      inflammatory cells removed, injured tissue cells replaced, and capillary barrier function
      re-established. Macrophages are key players in all of these. Here the investigators
      hypothesize that resident alveolar macrophages and recruited macrophages serve completely
      different functions, acting independently (i.e. division of labor) yet cooperatively
      (synergism).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resident alveolar macrophages and recruited macrophages will be distinguished from one another using multi-parameter flow cytometry, and the relative proportions enumerated</measure>
    <time_frame>7 days</time_frame>
    <description>Resident and recruited macrophages will be purified using fluorescence activated cell sorting (FACS) and subjected to RNA sequencing.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>LPS arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bronchoscopy with intrabronchial administration of lipopolysaccharide</intervention_name>
    <description>The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.</description>
    <arm_group_label>LPS arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written, informed consent

          2. Age 18-50

        Exclusion Criteria:

          1. Current or recent illness (past 2 weeks)

          2. Presence or prior history of cardiac, pulmonary or systemic disease

          3. Bleeding disorder, use of systemic anticoagulants or antiplatelet therapy

          4. American Society of Anesthesiology (ASA) class 2 or greater

          5. Immunocompromised state (HIV, immunoglobulin deficiency, systemic immunosuppressants)

          6. Use of any inhaled substance, including tobacco, marijuana, e-cigarrettes, cocaine,
             methamphetamines, or toxic vapors in the past 3 months or greater than 10 pack-year
             smoking history

          7. Alcohol use disorder or greater than 7 drinks/week for women or greater than 14
             drinks/week for men in the past 3 months

          8. Allergy or prior adverse reaction to lidocaine, midazolam or fentanyl

          9. Abnormal spirometry or electrocardiogram at time of screening

         10. Pregnant (based on urine pregnancy test) or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine Griesmer</last_name>
    <phone>303-398-1325</phone>
    <email>griesmerc@njhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Griesmer</last_name>
      <phone>303-398-1325</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

